
Sign up to save your podcasts
Or


Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
By STAT4.5
309309 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.

30,672 Listeners

1,898 Listeners

498 Listeners

9,514 Listeners

6,076 Listeners

395 Listeners

61 Listeners

86 Listeners

34 Listeners

505 Listeners

5,475 Listeners

19 Listeners

48 Listeners

387 Listeners

12 Listeners